Navigation Links
Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
Date:5/4/2009

DUBLIN, May 4 /PRNewswire/ -- Circ Pharma Limited ("Circ Pharma") and Elan Corporation plc ("Elan") today announced that they have entered into a Development Agreement to develop a chronotherapeutic formulation of Tramadol for the treatment of moderate to moderately severe pain.

The product incorporates Circ Pharma's proprietary drug delivery technology enabling once daily dosing. Circ's technology provides for minimized delivery to the body during sleeping hours, acceleration of drug absorption immediately prior to the waking hours and the subsequent maintenance of efficacious drug levels for the remainder of the waking hours. Circ has successfully completed Phase I testing on the product.

Currently the worldwide market for pain treatments is worth about US$26 billion and is forecast to grow to about $31 billion by 2011. In the US and Europe the moderate to severe pain market was estimated to be worth about $6.7 billion in 2007. The tramadol market in the US and Europe was worth about $1.1 billion in 2008.

Circ Pharma intends to seek a licensing partner for worldwide commercial distribution of the product.

The agreement with Elan provides that Elan support the continued formulation and manufacturing activities required to seek regulatory approval for this product in the United States and elsewhere. "Elan's extensive experience, know-how and technology for the development and manufacture of scheduled products for the US market will ensure that we can quickly and efficiently complete all the development and clinical activities required for Chrono Tramadol" said Circ Pharma's Chief Technical Officer, Margot Foynes.

About Circ Pharma

Circ Pharma is a specialty pharmaceutical product development company whose mission is to develop differentiated novel formulations of products based on existing drugs that provide incremental patient benefit. Circ Pharma has a strong intellectual property portfolio and technology in the areas of targeted and chronotherapeutic drug delivery and a broad clinical stage pipeline of novel product opportunities in a number of indications including cardiovascular and pain indications. http://www.circpharma.com

    Further Information:

    Media Contact
    Mr. Ray Gordon, Gordon MRM
    Telephone: +353-1-6650450
    E-mail: ray@gordonmrm.ie



'/>"/>
SOURCE Circ Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
2. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
3. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
4. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
5. Idenix Pharmaceuticals Reports First Quarter Financial Results
6. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. Vanda Pharmaceuticals Reports First Quarter 2009 Results
11. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec 5, 2016 Research and ... "Biomarkers - Technologies, Markets and Companies" to their offering. ... , , ... their discovery using various -omics technologies such as proteomics and metabolomics. ... new tests are also based on biomarker. Currently the ...
(Date:12/5/2016)... 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the ... and Safety Monitoring Board (DSMB) for the Company,s ... (CVD) patients has completed a second planned safety ... as planned without any modifications. The DSMB reviewed ... or efficacy concerns were identified. The DSMB will ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year extension ... federally funded research and development is welcome news for the photonics community, say ... , As part of the National Defense Authorization Act (NDAA) compromise agreement finalized ...
(Date:12/2/2016)... 2016 More than $4.3 million was raised last ... DHMD ). The gala was held at the American Museum ... and honored Alan Alda and ... and medicine and the public understanding of science. Since the ... event has raised $40 million for the Laboratory,s research and ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
Breaking Biology News(10 mins):